(0.13%) 5 138.25 points
(0.09%) 38 477 points
(0.21%) 17 883 points
(-0.24%) $83.65
(1.72%) $1.956
(0.13%) $2 350.30
(0.44%) $27.66
(1.60%) $936.85
(-0.17%) $0.933
(-0.27%) $10.99
(-0.28%) $0.798
(1.35%) $93.11
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 12.23%
@ $5.48
发出时间: 15 Feb 2024 @ 04:23
回报率: -24.02%
上一信号: Feb 15 - 01:19
上一信号:
回报率: 1.96 %
Live Chart Being Loaded With Signals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema...
Stats | |
---|---|
今日成交量 | 2.31M |
平均成交量 | 3.18M |
市值 | 857.58M |
EPS | $0 ( 2024-02-26 ) |
下一个收益日期 | ( $-0.220 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.53 |
ATR14 | $0.00900 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Thackray Helen M. | Sell | 7 525 | Common Stock |
2024-02-29 | Milano Vincent | Buy | 999 | Common Stock |
2024-02-29 | Heggie Theresa | Buy | 999 | Common Stock |
2024-01-03 | Stonehouse Jon P | Sell | 20 000 | Common Stock |
2024-01-03 | Stonehouse Jon P | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
75.11 |
Last 100 transactions |
Buy: 4 343 991 | Sell: 822 588 |
音量 相关性
BioCryst Pharmaceuticals 相关性 - 货币/商品
BioCryst Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $331.41M |
毛利润: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2023 |
营收: | $331.41M |
毛利润: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2022 |
营收: | $270.83M |
毛利润: | $264.23M (97.57 %) |
EPS: | $-1.330 |
FY | 2021 |
营收: | $157.17M |
毛利润: | $149.91M (95.38 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。